Literature DB >> 620051

Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization.

Y Inada, B Hessel, B Blombäck.   

Abstract

Human fibrinogen was illuminated in the presence of methylene blue. The resulting photooxidized fibrinogen was devoid of polymerization activity and thrombin-induced coagulability. The initial rate of the thrombin catalysed release of fibrinopeptides from photooxidized fibrinogen was normal. It was shown that illumination of photooxidized fibrinogen and photooxidized fragment N-DSK caused the modification of histidine residues. Tryptophan residues were also modified. When fibrinogen was photooxidized immediately after the addition of thrombin, the capacity to polymerize was lost. The inhibition of polymerization was less marked when oxidation was initiated at the time when polymerization began or thereafter. Photooxidized fibrinogen acts as an inhibitor of the polymerization of fibrin monomers. Photooxidized fibrinogen has affinity for thrombin-activated fibrinogen-Sepharose and thrombin-activated fragment N-DSK-Sepharose. When the former conjugate is illuminated in the presence of methylene blue its affinity for fibrinogen is decreased. It is concluded that the fragment N-DSK domain of fibrinogen is affected by photooxidation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620051     DOI: 10.1016/0005-2795(78)90459-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  No evidence for neoantigens in human plasma after photochemical virus inactivation.

Authors:  H Mohr; J Knüver-Hopf; B Lambrecht; H Scheidecker; H Schmitt
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

Review 2.  Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots.

Authors:  Marissa Martinez; John W Weisel; Harry Ischiropoulos
Journal:  Free Radic Biol Med       Date:  2013-07-11       Impact factor: 7.376

3.  Photodynamic treatment of pooled coumarin plasma for external quality assessment of the prothrombin time.

Authors:  A M van den Besselaar; A C Moor
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

4.  Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System.

Authors:  Ute Gravemann; Manuela Kusch; Herbert Koenig; Harald Mohr; Thomas H Mueller
Journal:  Transfus Med Hemother       Date:  2009-03-04       Impact factor: 3.747

5.  Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor.

Authors:  Ioannis Parastatidis; Leonor Thomson; Anne Burke; Irina Chernysh; Chandrasekaran Nagaswami; Jetze Visser; Sheryl Stamer; Daniel C Liebler; George Koliakos; Harry F G Heijnen; Garret A Fitzgerald; John W Weisel; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

6.  Characterization of the amino acids of bovine fibrinogen involved in the fibrinogen-thrombin interaction of the blood clotting process. Comparison with the milk clotting process.

Authors:  N M Kaye; P Jollès
Journal:  Mol Cell Biochem       Date:  1978-08-16       Impact factor: 3.396

7.  Inflammation induces fibrinogen nitration in experimental human endotoxemia.

Authors:  Sean P Heffron; Ioannis Parastatidis; Marina Cuchel; Megan L Wolfe; Mahlet G Tadesse; Emille R Mohler; Harry Ischiropoulos; Daniel J Rader; Muredach P Reilly
Journal:  Free Radic Biol Med       Date:  2009-07-22       Impact factor: 7.376

8.  Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism.

Authors:  Marissa Martinez; Adam Cuker; Angela Mills; Richard Lightfoot; Yiying Fan; W H Wilson Tang; Stanley L Hazen; Harry Ischiropoulos
Journal:  Free Radic Biol Med       Date:  2012-05-10       Impact factor: 7.376

9.  Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review.

Authors:  Judith J de Vries; Charlotte J M Snoek; Dingeman C Rijken; Moniek P M de Maat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-09       Impact factor: 8.311

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.